

# discover mor

See how MorphoSys  
is taking on some  
of the world's most  
serious diseases

**morphosys**

## Continually seeking answers

For nearly 30 years, MorphoSys has helped to elevate the standard for how antibodies will be made in the future, with innovative technology that enables their use as research, diagnostic, and therapeutic tools.

**1992**

Founded by Managing Director Simon Moroney in Munich, Germany

**1993–2011**

Advancing antibody science to develop novel and innovative approaches to treating cancer

**1997–2017**

Developed licensing agreements with partners including Novartis, Janssen, and Pfizer

**Since 2007**

Developing proprietary drug candidates through partnerships with GSK, Xencor, and I-Mab Biopharma, among others

**2018**

Nasdaq IPO Opening MorphoSys US Inc.

**2019**

Appointed Jean-Paul Kress CEO; established US headquarters in Boston, with David Trexler as President of MorphoSys US

# mor to come...

## Pursuing new paths to progress

MorphoSys is dedicated to bringing breakthrough medicines in oncology to the market to help address unmet needs for patients with B-cell malignancies.

### One of the broadest pipelines in biotech

- >100 distinct drugs currently in research and development
- >25 therapeutic antibodies in clinical trials as potential novel treatment options for severe and life-threatening diseases

*“This is a dynamic and outstanding time for MorphoSys, and I look forward to working to deliver innovative medicines to patients all over the globe.”*

*–Jean-Paul Kress, CEO, MorphoSys*

## Developing the medicines of tomorrow

Our mission is to make exceptional, innovative biopharmaceuticals to help improve the lives of patients suffering from serious diseases.

### Our focus is on cancer.

Innovative technologies and smart development strategies are central to our approach.

The MorphoSys logo is located in the bottom right corner of the page. It features the word "morphosys" in a bold, lowercase, sans-serif font. The letters are dark blue, and the "o"s are stylized with a slight gap between them. The background of the logo area is a light blue gradient.



# MorphoSys



*“We have an obligation and are privileged to work toward delivering life-changing therapy to patients in need.”*

*–David Trexler, President, MorphoSys US*

## **This is only the beginning.**

Connect with MorphoSys to learn more about our company and our clinical trial programs.

**Website:** [www.morphosys.com](http://www.morphosys.com)

**Twitter:** @MorphoSys

**Office:** 470 Atlantic Avenue, Boston, MA 02210 US

**E-mail:** [info.us@morphosys.com](mailto:info.us@morphosys.com)